Strides Begins Biosimilar Filings With Teriparatide

Expands COVID-19 Ambitions

 
• By Vibha Ravi

Strides files for a biosimilar to Eli Lilly’s Forteo (teriparatide) in the EU, marking the beginning of its journey in the biosimilars segment. Meanwhile, it hopes to enter a manufacturing tie-up with COVID-19 vaccine players in H2 while also planning a launch of favipiravir in markets outside India.

Rear view of an athlete starting his sprint on an all-weather running track. Runner using starting block to start his run on race track.
Strides Is Beginning Its Biosimilars Foray Through Stelis • Source: Shutterstock

More from Business

More from Scrip